Cargando…
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and...
Autores principales: | Sato, Y, Maeda, Y, Shomura, H, Sasatomi, T, Takahashi, M, Une, Y, Kondo, M, Shinohara, T, Hida, N, Katagiri, K, Sato, K, Sato, M, Yamada, A, Yamana, H, Harada, M, Itoh, K, Todo, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/ https://www.ncbi.nlm.nih.gov/pubmed/15054451 http://dx.doi.org/10.1038/sj.bjc.6601711 |
Ejemplares similares
-
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients
por: Maeda, Y, et al.
Publicado: (2002) -
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients
por: Shomura, H, et al.
Publicado: (2004) -
UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour
por: Tsuda, N, et al.
Publicado: (2002) -
Overexpression of hypoxia-inducible-factor 1α(HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage
por: Kurokawa, T, et al.
Publicado: (2003) -
RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer
por: Oshikiri, T, et al.
Publicado: (2001)